Chronopharmacology of glucocorticoids
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Glucocorticoids influence a wide array of metabolic, anti-inflammatory, immunosuppressive, and cognitive signaling processes, playing an important role in homeostasis and preservation of normal organ function. Synthesis is regulated by the hypothalamic-pituitary-adrenal (HPA) axis of which cortisol is the primary glucocorticoid in humans. Synthetic glucocorticoids are important pharmacological agents that augment the anti-inflammatory and immunosuppressive properties of endogenous cortisol and are widely used for the treatment of asthma, Crohn’s disease, and rheumatoid arthritis, amongst other chronic conditions. The homeostatic activity of cortisol is disrupted by the administration of synthetic glucocorticoids and so there is interest in developing treatment options that minimize HPA axis disturbance while maintaining the pharmacological effects. Studies suggest that optimizing drug administration time can achieve this goal. The present review provides an overview of endogenous glucocorticoid activity and recent advances in treatment options that have further improved patient safety and efficacy with an emphasis on chronopharmacology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stress and disorders of the stress system
Chrousos, G. P. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.106 · Cited by 3,215 · cited 21×
“Kino T, Charmandari E, Chrousos GP, Glucocorticoid receptor: implications for rheumatic diseases, Clin Exp Rheumatol, 29 (2011) S32–41.”
BackgroundInfluentialAntiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149 · cited 2×
“Generally, low levels of glucocorticoids are associated with more severe inflammatory responses due to rising levels of proinflammatory mediators, whereas high levels of glucocorticoids, particularly in the absence of inflammation, leads to increased risk of infections and issues with immunity due to the immunosuppres…”
BackgroundAllostatic load biomarkers of chronic stress and impact on health and cognition
Juster, R.-P., McEwen, B. S., & Lupien, S. J. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.10.002 · Cited by 2,565 · cited 1×
“When an individual is exposed to stress, the HPA axis becomes activated, leading to an increase in cortisol secretion, which along with other mediators, facilitates the modification of underlying physiological properties in the body and brain for maintenance of homeostasis, a process referred to as allostasis [48, 49].”
BackgroundDibner, C., Schibler, U., & Albrecht, U. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135821 · Cited by 2,421
Endocrinology of the stress response
Charmandari, E., Tsigos, C., & Chrousos, G. (2005) · Annual Review of Physiology · doi:10.1146/annurev.physiol.67.040403.120816 · Cited by 1,799 · cited 1×
“As such, the mineralocorticoid receptors respond to low glucocorticoid concentrations and glucocorticoid receptors respond to both basal and stress concentrations [60].”
BackgroundMolecular architecture of the mammalian circadian clock
Partch, C. L., Green, C. B., & Takahashi, J. S. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.07.002 · Cited by 1,449 · cited 1×
“The oscillatory behavior is driven by signals received from the central pacemaker located in the hypothalamic suprachiasmatic nucleus (SCN) and external cues, such as stress [8, 9].”
BackgroundLiu, D., Ahmet, A., Ward, L., Krishnamoorthy, P., Mandelcorn, E. D., Leigh, R., Brown, J. P., Cohen, A., & Kim, H. (2013) · Allergy, Asthma & Clinical Immunology · doi:10.1186/1710-1492-9-30 · Cited by 1,268
Stress Hormones, Proinflammatory and Antiinflammatory Cytokines, and Autoimmunity
ELENKOV, I. J., & CHROUSOS, G. P. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04229.x · Cited by 983
Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.
Czock, D., Keller, F., Rasche, F. M., & H??ussler, U. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00003 · Cited by 886 · cited 10×
“All drugs are eliminated by hepatic metabolism and renal excretion of inactive metabolites as well as some un-metabolized drug [85].”
BackgroundInfluentialCircadian Rhythms: Mechanisms and Therapeutic Implications
Levi, F., & Schibler, U. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105208 · Cited by 645
Charmandari, E., Nicolaides, N. C., & Chrousos, G. P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61684-0 · Cited by 644
Population‐based assessment of adverse events associated with long‐term glucocorticoid use
Curtis, J. R., Westfall, A. O., Allison, J., Bijlsma, J. W., Freeman, A., George, V., Kovac, S. H., Spettell, C. M., & Saag, K. G. (2006) · Arthritis Care & Research · doi:10.1002/art.21984 · Cited by 595
The Functional and Clinical Significance of the 24-Hour Rhythm of Circulating Glucocorticoids
Oster, H., Challet, E., Ott, V., Arvat, E., de Kloet, E. R., Dijk, D.-J., Lightman, S., Vgontzas, A., & Van Cauter, E. (2017) · Endocrine Reviews · doi:10.1210/er.2015-1080 · Cited by 548 · cited 5×
“Glucocorticoids impact the rhythmic expression of circadian genes in almost all tissues [14].”
BackgroundInfluentialThe coming out of the brain mineralocorticoid receptor
Joëls, M., Karst, H., DeRijk, R., & de Kloet, E. R. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2007.10.005 · Cited by 481 · cited 4×
“Together, the various receptor types are responsible for maintaining the fast and slow signaling cascades controlled by glucocorticoids corresponding with the non-genomic and genomic mechanisms of action, respectively [57].”
BackgroundInfluentialStress, the Stress System and the Role of Glucocorticoids
Nicolaides, N. C., Kyratzi, E., Lamprokostopoulou, A., Chrousos, G. P., & Charmandari, E. (2015) · Neuroimmunomodulation · doi:10.1159/000362736 · Cited by 477
Schäcke, H., Schottelius, A., Döcke, W.-D., Strehlke, P., Jaroch, S., Schmees, N., Rehwinkel, H., Hennekes, H., & Asadullah, K. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0300372101 · Cited by 466
Energy regulation and neuroendocrine–immune control in chronic inflammatory diseases
Straub, R. H., Cutolo, M., Buttgereit, F., & Pongratz, G. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02218.x · Cited by 382
Oakley, R. H., & Cidlowski, J. A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.r110.179325 · Cited by 373 · cited 1×
“Interestingly, the same individual can show significant variability in the magnitude and specificity of action across tissues and even across phases of the cell cycle, requiring a deeper understanding of the signal transduction pathways involved in both therapeutic and adverse effects [173].”
BackgroundModified-release hydrocortisone to provide circadian cortisol profiles
Debono, M., Ghobadi, C., Rostami-Hodjegan, A., Huatan, H., Campbell, M. J., Newell-Price, J., Darzy, K., Merke, D. P., Arlt, W., & Ross, R. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2380 · Cited by 322 · cited 3×
“In contrast, dexamethasone has a much longer half-life of 36 to 72 hours and is typically administered at lower doses because of its potent glucocorticoid receptor activity and longer duration of action [91].”
BackgroundGlucocorticoid sensitivity in health and disease
Quax, R. A., Manenschijn, L., Koper, J. W., Hazes, J. M., Lamberts, S. W. J., van Rossum, E. F. C., & Feelders, R. A. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.183 · Cited by 310
Fardet, L., Petersen, I., & Nazareth, I. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11071009 · Cited by 287
Spiga, F., Walker, J. J., Terry, J. R., & Lightman, S. L. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c140003 · Cited by 267
Beishuizen, A., Thijs, L. G., & Vermes, I. (2001) · Intensive Care Medicine · doi:10.1007/s001340101073 · Cited by 245
Review: Replication of cortisol circadian rhythm: new advances in hydrocortisone replacement therapy
Chan, S., & Debono, M. (2010) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018810380214 · Cited by 243
Isidori, A. M., Venneri, M. A., Graziadio, C., Simeoli, C., Fiore, D., Hasenmajer, V., Sbardella, E., Gianfrilli, D., Pozza, C., Pasqualetti, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30398-4 · Cited by 211
Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD
Burt, M. G., Roberts, G. W., Aguilar-Loza, N. R., Frith, P., & Stranks, S. N. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2729 · Cited by 203 · cited 4×
“Similar findings were observed for patients receiving prednisolone to treat COPD [158].”
ResultInfluentialTreatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis
Paragliola, R. M., Papi, G., Pontecorvi, A., & Corsello, S. M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102201 · Cited by 181 · cited 1×
“A brief summary of pharmacodynamics for select glucocorticoids are provided in Table 3 (adapted from [75]).”
BackgroundThe low-dose dexamethasone suppression test: a reevaluation in patients with Cushing's syndrome
Findling, J. W., Raff, H., & Aron, D. C. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030207 · Cited by 165 · cited 1×
“Dexamethasone is also commonly used to suppress the HPA axis to mimic disease states for analysis of other synthetic glucocorticoids [90, 98, 99].”
BackgroundPrednisolone Pharmacokinetics and Pharmacodynamics in Relation to Sex and Race
Magee, M. H., Blum, R. A., Lates, C. D., & Jusko, W. J. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122012733 · Cited by 125 · cited 8×
“different patient subgroups may be more susceptible to adverse effects due to differences in drug exposure and sensitivity [105].”
BackgroundMethodInfluentialOptimized glucocorticoid therapy: teaching old drugs new tricks
Strehl, C., & Buttgereit, F. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.01.026 · Cited by 118
Variation in absorption and half-life of hydrocortisone influence plasma cortisol concentrations
Hindmarsh, P. C., & Charmandari, E. (2015) · Clinical Endocrinology · doi:10.1111/cen.12653 · Cited by 66 · cited 3×
“For example, greater suppression of the HPA axis is usually observed with higher doses due to increased negative feedback signals [53, 89].”
BackgroundInfluentialSong, Q.-Q., Xie, W.-Y., Tang, Y.-J., Zhang, J., & Liu, J. (2017) · Pharmacogenomics · doi:10.2217/pgs-2016-0151 · Cited by 40
Melin, J., Parra-Guillen, Z. P., Hartung, N., Huisinga, W., Ross, R. J., Whitaker, M. J., & Kloft, C. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0575-8 · Cited by 17
Cited by
Glucocorticoid induced adrenal insufficiency
Prete, A., & Bancos, I. (2021) · BMJ · doi:10.1136/bmj.n1380 · Cited by 155
Circadian rhythms and the HPA axis: A systems view
Androulakis, I. P. (2021) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1518 · Cited by 55
Self-citationLi, Y., Lu, L., & Androulakis, I. P. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.08.005 · Cited by 17
Self-citationMelin, J., Parra-Guillen, Z. P., Hartung, N., Huisinga, W., Ross, R. J., Whitaker, M. J., & Kloft, C. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0575-8 · Cited by 17
Metadata
- Authors
- Scherholz, M. L., Schlesinger, N., & Androulakis, I. P.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 151-152
- Pages
- 245-261
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2916699108
- Cited by
- 144
- References
- 33
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.